XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule Of Share Based Compensation Shares Authorized Under Stock Plans Issued And Avaliability
The following table summarizes the number of shares of common stock authorized for issuance under the 2019 Plan, the number of stock-based awards granted (net of expired or cancelled awards) under the 2019 Plan and the number of shares of common stock available for the grant of stock-based awards under the 2019 Plan:

Common stock authorized11,000
Stock-based awards, including restricted stock and stock options granted, net of expired or cancelled awards(5,912)
Common stock available for grant of stock-based awards as of March 31, 20235,088
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Total equity-based compensation for the three months ended March 31, 2023 and 2022 was as follows:

 Three Months Ended March 31,
 20232022
Restricted stock$5,393 $5,062 
Stock options746 918 
Total$6,139 $5,980 
Schedule Of Cash Proceeds And Intrinsic Values For Stock Options Exercised
Cash proceeds and intrinsic values related to total stock options exercised during the three months ended March 31, 2023 and 2022 were as follows:
 Three Months Ended March 31,
 20232022
Proceeds from stock options exercised$264 $275 
Intrinsic value of stock options exercised$134 $172 
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used The following weighted average assumptions were used for stock options granted during the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
 20232022
Volatility
47.7%
 45.1%
Risk free interest rate
4.0%
1.2%
Expected life in years
5.0
5.0
Dividend yield2.6%1.8%
Weighted average fair value$11.86$15.60
Schedule of Share-based Compensation, Stock Options, Activity
Activity relating to stock options granted under the Company’s plans during the three months ended March 31, 2023 was as follows:
 Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual TermAggregate Intrinsic Value
Outstanding at January 1, 20232,766$29.82   
Granted831.96   
Exercised(11)24.26   
Forfeited(3)46.28   
Outstanding at March 31, 20232,760$29.83 1.8 years$19,529 
Exercisable at March 31, 20232,612$29.36 1.6 years$19,417 
Schedule of Nonvested Share Activity
The following table summarizes restricted stock activity during the three months ended March 31, 2023 and 2022:

Three Months Ended March 31,
 20232022
 Number of SharesWeighted Average Fair Value at Grant DateNumber of SharesWeighted Average Fair Value at Grant Date
Outstanding at January 1,2,111$28.45 2,849$23.80 
Granted28433.69 32341.82 
Vested(229)34.58 (201)31.67 
Forfeited(5)38.15 (1)32.13 
Outstanding at March 31,2,161$28.47 2,970$25.22